Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

American Regent logo

American Regent

Status and phase

Completed
Phase 3

Conditions

Restless Legs Syndrome (RLS)

Treatments

Other: Placebo
Drug: Injectafer

Study type

Interventional

Funder types

Industry

Identifiers

NCT02397057
1VIT14037

Details and patient eligibility

About

This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 12 months. The subject's participation in the study will be for approximately 1 year from Day 0.

Full description

This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 12 months. Subjects will visit the clinic on Days 0 and 5 for treatment, and then on Days 14, 42, 168, and 365. In between the clinic visits subjects will be contacted remotely on Days 84, 126, 210, 252, 294, and 336. The subject's participation in the study will be for approximately 1 year from Day 0.

Enrollment

209 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female subject's ≥18 years of age, willing and able to give informed consent to the study.

RLS symptoms affirming diagnosis. The IRLS Diagnostic Criteria must be met:

  • An urge (distressing need) to move the legs usually associated with painful or uncomfortable sensations in the legs. The urge to move may be present without the uncomfortable sensations. The arms or other body parts may be involved in addition to the legs.
  • The urge to move or unpleasant sensations are worse or exclusively present at rest or inactivity, such as lying down or sitting.
  • The urge to move or unpleasant sensations are partially/temporarily relieved with walking or moving the legs.
  • The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. When symptoms are severe, the worsening at night may not be noticeable but must have been previously present.
  • Subjects should be on monotherapy for RLS. Treatment should be stable for at least 8 weeks prior to screening (See approved RLS Therapies/Regimen in Appendix III).
  • A score ≥15 on the IRLS Rating Scale at screening and on Day 0 prior to dosing.
  • Subjects on anti-depressants and sleep medications must be on a stable dose for at least 6 months.
  • Subject has regular sleep hours between 9 pm and 9 am.
  • Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of birth control: have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide with barrier, intrauterine device, or partner sterility.

Exclusion criteria

  • RLS 2° to other disease or injury.
  • Disorders that require treatment with the same medications used for RLS include: peripheral neuropathy and neurodegenerative disorders (i.e. Parkinson's Disease or Dementia).
  • Stage 4 - 5 CKD, subjects on dialysis or anticipated to start dialysis while participating in this study.
  • Any pain related (e.g., frequent muscle cramps, myalgia, fibromyalgia) or sleep related disorders (e.g. sleep apnea, unless on stable Continuous Positive Airway Pressure [CPAP]) which may confound the outcome measures.
  • Subjects with multiple sclerosis.
  • History of neuroleptic akathisia.
  • Parenteral iron use within 6 weeks prior to screening.
  • History of >10 blood transfusions in the past 2 years.
  • Anticipated need for blood transfusion during the study.
  • Known hypersensitivity reaction to any component of Injectafer® (Ferric Carboxymaltose).
  • Previously randomized to Injectafer® (FCM or VIT-45) in a clinical trial.
  • Current, active or acute or chronic infection other than viral upper respiratory tract infection
  • Malignancy (other than basal or squamous cell skin cancer or the subject has been cancer free for ≥ 5 years).
  • Pregnant or lactating women.
  • Seizure disorder currently being treated with medication.
  • Baseline ferritin ≥300 ng/mL.
  • Baseline TSAT ≥45%.
  • History of hemochromatosis, hemosiderosis, or other iron storage disorders.
  • AST or ALT greater than 2 times the upper limit of normal (ULN).
  • Hemoglobin greater than the ULN.
  • Known positive hepatitis B antigen (HBsAg), unless positive test can be attributed to receipt of hepatitis B vaccination in childhood or hepatitis C viral antibody (HCV) with evidence of active hepatitis (i.e., AST/ALT greater than the upper limit of normal).
  • Known positive HIV-1/HIV-2 antibodies (anti-HIV).
  • Received an investigational drug within 30 days before randomization.
  • Chronic alcohol or drug abuse within the past 6 months.
  • Any other pre-existing laboratory abnormality, medical condition or disease, which per the investigator may put the subject at risk if they participate in the study.
  • Subject unable or unwilling to comply with the study requirements.

Trial design

209 participants in 2 patient groups, including a placebo group

Injectafer
Active Comparator group
Description:
Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
Treatment:
Drug: Injectafer
Normal Saline
Placebo Comparator group
Description:
IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
Treatment:
Other: Placebo

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems